The nasopharygeal epithelial carcinoma (NPC) has distinct epidemiology and treatment regimens from other head and neck cancers. Our proposed NRS2002 scale represents a simple, clinically useful tool for nutritional risk screening in NPC. Therefore, we proposed a revised NRS2002 scale, and found that it provides a better risk stratification than the original or regrouping scales for predicting DFS (area under the curve = 0.530 vs 0.554 vs 0.577 P < .05), OS ( AUC = 0.534 vs 0.563 vs 0.582 P < .05), DMFS ( AUC = 0.531 vs 0.567 vs 0.590 P < .05) and LRRFS ( AUC = 0.529 vs 0.542 vs 0.564 P < .05 except scale A vs B). Survival outcomes were comparable between patients with NRS2002 3 (regrouping scale) had significantly different 5‐year disease‐free survival ( DFS 82.7% vs 75.0%, P < .001), overall survival ( OS 88.8% vs 84.1%, P = .001), distant metastasis‐free survival ( DMFS 90.2% vs 85.9%, P = .001) and locoregional relapse‐free survival ( LRRFS 91.6% vs 87.2%, P = .001). We employed a big‐data intelligence database platform at our center and identified 3232 eligible patients treated between 20. We conducted a large‐scale study to address this issue. Little is known about the value of the nutritional risk screening 2002 ( NRS2002) scale in nasopharyngeal carcinoma ( NPC).
0 kommentar(er)
